Pembrolizumab (Keytruda®) as monotherapy is indicated for the adjuvant treatment of adults with Stage III melanoma and lymph node involvement who have undergone complete resection.
| NCPE Assessment Process | Complete |
| Rapid review commissioned | 19/11/2018 |
| Rapid review completed | 07/12/2018 |
| Rapid Review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of pembrolizumab compared with the current standard of care. |
| Full pharmacoeconomic assessment commissioned by the HSE | 19/12/2018 |
| Pre-submission consultation with Applicant | 14/01/2019 |
| Submission received from Applicant | 16/07/2019 |
| Preliminary review sent to Applicant | 13/11/2019 |
| NCPE assessment recommenced | 12/12/2019 |
| Factual Accuracy sent to Applicant | 01/04/2020 |
| NCPE assessment recommenced | 08/04/2020 |
| NCPE assessment complete | 15/05/2020 |
| NCPE assessment outcome | The NCPE recommends that pembrolizumab be considered for reimbursement if cost-effectiveness can be improved relative to existing treatments*. |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.